Patents Represented by Attorney, Agent or Law Firm Lorie Ann Morgan
-
Patent number: 6307043Abstract: The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.Type: GrantFiled: January 21, 2000Date of Patent: October 23, 2001Assignee: Glaxo Wellcome Inc.Inventors: Stanley Dawes Chamberlain, Jeffrey H. Tidwell
-
Patent number: 6297276Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerbral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.Type: GrantFiled: January 26, 2001Date of Patent: October 2, 2001Assignee: GlaxoSmithKlineInventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Cleveland Bigham, Eric Steven Furfine, Edward Patrick Garvey
-
Patent number: 6284770Abstract: This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.Type: GrantFiled: April 5, 2000Date of Patent: September 4, 2001Assignee: Glaxo Wellcome Inc.Inventors: Allen Wayne Mangel, Allison Ruth Northcutt
-
Patent number: 6265449Abstract: The invention relates to an aqueous pharmaceutical composition for oral administration comprising ranitidine, or a pharmaceutically acceptable salt thereof, characterized in that the composition contains low color, metal, turbidity (LCMT) sucrose.Type: GrantFiled: December 10, 1999Date of Patent: July 24, 2001Assignee: Glaxo Wellcome Inc.Inventor: Ralph Boyer Caricofe
-
Patent number: 6225305Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.Type: GrantFiled: February 28, 2000Date of Patent: May 1, 2001Assignee: Glaxo Wellcome Inc.Inventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Cleveland Bigham, Eric Steven Furfine, Edward Patrick Garvey
-
Patent number: 6204249Abstract: The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.Type: GrantFiled: July 13, 1998Date of Patent: March 20, 2001Assignee: Glaxo Wellcome Inc.Inventors: Stanley Dawes Chamberlain, George Walter Koszalka, Jeffrey H. Tidwell, Nanine Agneta Vandraanen
-
Patent number: 6187789Abstract: Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z1 and Z2 are methyl; W1 and W2 are carbon; and A is a pharmaceutically acceptable anion.Type: GrantFiled: January 19, 2000Date of Patent: February 13, 2001Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano
-
Patent number: 6177445Abstract: Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X1 and X2 are independently halogen; ha and hb are independenity from 0 to 2; Z1 and Z2 are indepentdently hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl with the proviso that Z1 and Z2 are not both hydrogen; Y1, Y2, and Y3 and Y4 are independently hydrogen, halogen or C1-3 alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if ha and hb are both 0, then r is 0 and n is 0 to 2; R1 to R14 are independently hydrogen, halogen, C1-3 alkoxy, or R2 and R3 together with the carbon atoms to which they are bonded, R5 and R6 together with the carbon atoms to which they are bonded, R9 and R10 together with the carbon atoms to which they are bonded, R12 and R13 together with the carbon atoms to which they are bonded, mayType: GrantFiled: December 22, 1999Date of Patent: January 23, 2001Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano
-
Patent number: 6124284Abstract: Novel compounds of formula (1) together with their salts and solvates have a number of uses in medicine, in particular as central muscle relaxants.Type: GrantFiled: July 16, 1998Date of Patent: September 26, 2000Assignee: Glaxo Wellcome Inc.Inventors: James Leroy Kelley, Gregory Cooksey Rigdon, Barrett Randolph Cooper, Ed Williams McLean, David Lee Musso, Gloria Faye Orr, Jeffrey Leaman Selph, Virgil Lee Styles
-
Patent number: 6090846Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.Type: GrantFiled: March 28, 1996Date of Patent: July 18, 2000Assignee: Glaxo Wellcome Inc.Inventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Steven Furfine, Edward Patrick Garvey
-
Patent number: 6077832Abstract: The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.Type: GrantFiled: January 6, 1997Date of Patent: June 20, 2000Assignee: Glaxo Wellcome Inc.Inventors: Stanley Dawes Chamberlain, Susan Mary Daluge, George Walter Koszalka
-
Patent number: 6071939Abstract: A composition comprising diethyl (E)-4-[2-[(tert-butyloxycarbonyl)vinyl]phenyl-1,4-dihydro-2,6-dimethylpyri dine-3,5-dicarboxylate (lacidipine) and 4'-[[2-n-propyl-4-methyl-6 -(1-methylbenziimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2 -carboxylic acid (telmisartan) or a physiologically functional derivative thereof.Type: GrantFiled: May 4, 1999Date of Patent: June 6, 2000Assignees: Glaxo Group Limited, Boehringer Ingelheim GmbHInventors: Giovanni Gaviraghi, Mauro Quartaroli
-
Patent number: 6063923Abstract: The present invention relates to a method for the preparation of camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I') known by the chemical name "7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin ", which comprises cyclising the compound of formula (II'), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I') is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer, and/or if desired, converting the resulting compound of formula (I') or a salt thereof into a physiologically acceptable salt or solvate thereof.Type: GrantFiled: November 1, 1996Date of Patent: May 16, 2000Assignees: Glaxo Wellcome Inc., North Carolina State UniversityInventors: Francis Gerard Fang, Edward McDonald Huie, Shiping Xie, Daniel L. Comins
-
Patent number: 5998400Abstract: The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, and associated diseases such as atherosclerosis.Type: GrantFiled: May 1, 1997Date of Patent: December 7, 1999Assignee: Glaxo Wellcome Inc.Inventors: Lawrence Edward Brieaddy, Anthony Louis Handlon, Gordon Lewis Hodgson, Jr.
-
Patent number: 5998398Abstract: The present invention relates to benzimidazole derivatives of formula (I) wherein: R.sup.1 represents H, C.sub.1-4 alkyl, C.sub.3-5 cycloalkyl; R.sup.2 represents H, C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 together form with the nitrogen a 4 or 5 membered heterocyclic ring; R.sup.3 represents BR.sup.4 or R.sup.4 wherein B represents a bridging group --C(O)NH--, --C(O)NC.sub.1-4 alkyl-, or C(O)O-- and R.sup.4 represents H, C.sub.1-4 alkyl, C.sub.2-6 alkenyl or halo (preferably fluoro); and each n is an integer independently selected from 0, 1, or 2 (preferably 0 or 1); and geometric isomers or mixtures thereof; and physiologically functional derivatives thereof, and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to their preparation and pharmaceutical formulations containing them.Type: GrantFiled: July 1, 1998Date of Patent: December 7, 1999Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Marc Werner Andersen
-
Patent number: 5998605Abstract: The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.Type: GrantFiled: December 18, 1998Date of Patent: December 7, 1999Assignee: Glaxo Wellcome Inc.Inventors: Stanley Dawes Chamberlain, Susan Mary Daluge, George Walter Koszalka
-
Patent number: 5910494Abstract: The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.Type: GrantFiled: February 7, 1997Date of Patent: June 8, 1999Assignee: Glaxo Wellcome Inc.Inventor: Lawrence Edward Brieaddy
-
Patent number: 5874472Abstract: Compounds of formula (I) and salts, esters and amides thereof, wherein R.sup.1 is a C.sub.1-6 straight or branched chain alkyl group, a C.sub.3-6 cycloalkyl group, a thiol group optionally substituted by a C.sub.1-6 alkyl group, or an amino group optionally substituted by one or two alkyl or alkenyl groups; R.sup.2 is H, C.sub.1-7 straight or branched chain alkyl, C.sub.3-6 cycloalkyl, C.sub.2-7 alkenyl or benzyl; A is a 5 or 6 membered aromatic carbocyclic or heterocyclic ring which may optionally be substituted by one or more suitable substituents such as C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halo, nitro, cyano, trifluoro C.sub.1-6 alkyl, amino, C.sub.1-6 alkylamino or di C.sub.1-6 alkylamino; r is 0, 1 or 2; their use in medicine and in particular for conditions requiring inhibition of the NO Synthase enzyme, pharmaceutical formulations and processes for the preparation thereof are disclosed.Type: GrantFiled: March 18, 1996Date of Patent: February 23, 1999Assignee: Glaxo Wellcome Inc.Inventors: Barry George Shearer, Karl Witold Franzmann, Harold Francis Hodson
-
Patent number: 5866612Abstract: A class of acetamidine derivatives of general formula (I) ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR.sup.3 wherein X is oxygen, C(O).sub.m wherein m is 1 or 2, S(O).sub.n wherein n is 0, 1 or 2, or a group NR.sup.4 wherein R.sup.4 is hydrogen or C.sub.1-6 alkyl; and R.sup.3 is hydrogen, C.sub.1-6 alkyl, or a group NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl, provided that R.sup.3 is not NR.sup.5 R.sup.6 when X is oxygen or S(O).sub.n; R.sup.1a and R.sup.1b are independently selected from hydrogen and halo; R.sup.2 is a C.sub.1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R.sup.2 being optionally substituted by one or more groups independently selected from halo; N.sub.3 ; nitro; CF.sub.3 ; ZR.sup.7 wherein Z is oxygen, C(O).sub.m' wherein m' is 1 or 2, S(O).sub.n' wherein n' is 0, 1 or 2, or a group NR.sup.8 wherein R.sup.Type: GrantFiled: June 17, 1997Date of Patent: February 2, 1999Assignee: Glaxo Wellcome Inc.Inventors: Jeffrey Alan Oplinger, Edward Patrick Garvey, Eric Steven Furfine, Barry George Shearer, Jon Loren Collins
-
Patent number: RE37438Abstract: A class of acetamidine derivatives of general formula (I) wherein R1 is hydrogen, C1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n; R1a and R1b are independently selected from hydrogen and halo; R2 is a C1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R2 being optionally substituted by one or more groups independently selected from halo; N3; nitro; CF3; ZR7 wherein Z is oxygen, C(O)m′ wherein m′ is 1 or 2, S(O)n′ wherein n′ is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or RType: GrantFiled: May 4, 1999Date of Patent: November 6, 2001Assignee: Glaxo Wellcome Inc.Inventors: Jeffrey Alan Oplinger, Edward Patrick Garvey, Eric Steven Furfine, Barry George Shearer, Jon Loren Collins